| Identification | Back Directory | [Name]
L-Leucinamide, L-leucyl-L-lysyl-D-leucyl-L-leucyl-L-lysyl-D-lysyl-L-leucyl-D-leucyl-D-lysyl-L-lysyl-L-leucyl-L-leucyl-D-lysyl-L-leucyl- | [CAS]
426264-61-1 | [Synonyms]
L-Leucinamide, L-leucyl-L-lysyl-D-leucyl-L-leucyl-L-lysyl-D-lysyl-L-leucyl-D-leucyl-D-lysyl-L-lysyl-L-leucyl-L-leucyl-D-lysyl-L-leucyl- | [Molecular Formula]
C90H174N22O15 | [MOL File]
426264-61-1.mol | [Molecular Weight]
1804.48 |
| Chemical Properties | Back Directory | [Boiling point ]
1761.3±65.0 °C(Predicted) | [density ]
1.105±0.06 g/cm3(Predicted) | [pka]
13.42±0.46(Predicted) | [Sequence]
Leu-Lys-{d-Leu}-Leu-Lys-{d-Lys}-Leu-{d-Leu}-{d-Lys}-Lys-Leu-Leu-{d-Lys}-Leu-Leu-NH2 |
| Hazard Information | Back Directory | [Uses]
D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance [1]. | [References]
[1] Ben Hur D, et al. Antimicrobial Peptides against Multidrug-Resistant Pseudomonas aeruginosa Biofilm from Cystic Fibrosis Patients. J Med Chem. 2022;65(13):9050-9062. DOI:10.1021/acs.jmedchem.2c00270 |
|
|